- Home
- MRBK vs BIOA Comparison
MRBK vs BIOA Comparison
Compare MRBK & BIOA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRBK
- BIOA
- Stock Information
- Founded
- MRBK 2004
- BIOA 2015
- Country
- MRBK United States
- BIOA United States
- Employees
- MRBK N/A
- BIOA N/A
- Industry
- MRBK Major Banks
- BIOA Biotechnology: Pharmaceutical Preparations
- Sector
- MRBK Finance
- BIOA Health Care
- Exchange
- MRBK Nasdaq
- BIOA Nasdaq
- Market Cap
- MRBK 162.3M
- BIOA 175.7M
- IPO Year
- MRBK 2017
- BIOA 2024
- Fundamental
- Price
- MRBK $14.41
- BIOA $8.24
- Analyst Decision
- MRBK Buy
- BIOA Hold
- Analyst Count
- MRBK 2
- BIOA 4
- Target Price
- MRBK $17.50
- BIOA $9.00
- AVG Volume (30 Days)
- MRBK 48.6K
- BIOA 555.8K
- Earning Date
- MRBK 10-23-2025
- BIOA 11-06-2025
- Dividend Yield
- MRBK 3.47%
- BIOA N/A
- EPS Growth
- MRBK 75.95
- BIOA N/A
- EPS
- MRBK 1.77
- BIOA N/A
- Revenue
- MRBK $109,758,000.00
- BIOA $5,917,000.00
- Revenue This Year
- MRBK $26.84
- BIOA N/A
- Revenue Next Year
- MRBK $8.90
- BIOA N/A
- P/E Ratio
- MRBK $8.15
- BIOA N/A
- Revenue Growth
- MRBK 18.84
- BIOA N/A
- 52 Week Low
- MRBK $11.16
- BIOA $2.88
- 52 Week High
- MRBK $17.33
- BIOA $20.37
- Technical
- Relative Strength Index (RSI)
- MRBK 43.57
- BIOA 67.66
- Support Level
- MRBK $14.35
- BIOA $7.60
- Resistance Level
- MRBK $14.88
- BIOA $8.37
- Average True Range (ATR)
- MRBK 0.38
- BIOA 0.40
- MACD
- MRBK -0.01
- BIOA -0.00
- Stochastic Oscillator
- MRBK 30.46
- BIOA 91.52
About MRBK Meridian Corporation
Meridian Corp is a bank holding company. Through its banking subsidiary, it operates as a full-service, state-chartered commercial bank providing personal, business lending, and deposit services. It operates in three reportable segments including Bank, Wealth, and Mortgage. The company generates maximum revenue from the Bank segment which consists of commercial and retail banking. It generates interest income from its lending (including leasing) and investing activities and is dependent on the gathering of lower-cost deposits from its branch network or borrowed funds from other sources for funding its loans.
About BIOA BioAge Labs Inc. Common Stock
Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its focus is metabolic disease, one of the greatest healthcare challenges. The pipeline Products of the company are NLRP3 inhibitors, APJ against, and others.